ANIX VS GLYC Stock Comparison

Performance

ANIX
10/100

ANIX returned -42.05% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

GLYC
10/100

GLYC returned -21.47% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ANIX
75/100

1 analysts offer 12-month price targets for ANIX. Together, they have an average target of 8, the most optimistic target put ANIX at 8 within 12-months and the most pessimistic has ANIX at 8.

GLYC
85/100

5 analysts offer 12-month price targets for GLYC. Together, they have an average target of 0, the most optimistic target put GLYC at 0 within 12-months and the most pessimistic has GLYC at 0.

Sentiment

ANIX
67/100

ANIX had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 1.57 posts, 0.29 comments, and 1.43 likes per day.

GLYC

"Sentiment" not found for GLYC

Technicals

ANIX
11/100

ANIX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

GLYC
64/100

GLYC receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ANIX
61/100

ANIX has missed earnings 3 times in the last 20 quarters.

GLYC
36/100

GLYC has missed earnings 3 times in the last 20 quarters.

Profit

ANIX
10/100

Out of the last 20 quarters, ANIX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

GLYC
10/100

Out of the last 20 quarters, GLYC has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

ANIX
34/100

ANIX has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

GLYC
55/100

GLYC has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Anixa Biosciences, Inc. Summary

Nasdaq / ANIX

Healthcare

Biotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

GlycoMimetics, Inc. Summary

Nasdaq / GLYC

Healthcare

Biotechnology

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Power up your portfolio